阿哌沙班与利伐沙班延长抗凝治疗处方模式
结果显示74.6%使用全剂量,25.4%使用减剂量;镰状细胞病在全剂量组更常见(14.5% vs 2.7%;P=0.01),5期慢性肾病在减剂量组更常见(3.3% vs 11%;P=0.01);血液/肿瘤专科医生更倾向处方减剂量(37.0% vs 22.4%;P=0.01)。
要点
- 多数VTE延长抗凝患者使用全剂量阿哌沙班或利伐沙班,减剂量仅占25.4%。
- 镰状细胞病与全剂量处方相关,5期慢性肾病与减剂量处方相关。
- 血液/肿瘤专科医生更倾向于处方减剂量抗凝药。
核心结论
- 尽管有指南建议延长抗凝可考虑减剂量,但大多数患者仍接受全剂量利伐沙班或阿哌沙班。
- 处方者选择剂量时可能考虑患者个体化的血栓和出血风险。
研究设计与样本
- 排除孕妇及非VTE适应症使用利伐沙班或阿哌沙班的患者。
主要发现
- 214例(74.6%)处方全剂量阿哌沙班或利伐沙班,73例(25.4%)处方减剂量。
- 镰状细胞病在全剂量组更常见(14.5% vs 2.7%;P=0.01)。
- 5期慢性肾病在减剂量组更常见(3.3% vs 11%;P=0.01)。
- 血液/肿瘤专科医生处方减剂量的比例高于全剂量(37.0% vs 22.4%;P=0.01)。
临床怎么用
- 临床药师应关注VTE延长抗凝治疗中减剂量方案的适用性,结合患者血栓与出血风险个体化评估。
- 对于合并5期慢性肾病等特殊患者,需评估减剂量抗凝的合理性。
局限性
- 单中心回顾性设计可能限制结论的外推性。
- 未报告剂量选择的具体依据及临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Reduced-dose apixaban or rivaroxaban has been suggested for extended-phase anticoagulant therapy for prevention of venous thromboembolism (VTE). The uptake of this suggestion in clinical practice is unclear. The purpose of this study was to describe the prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy in an urban university setting. METHODS: This was a retrospective, single-center, observational study in patients 18 years of age or older with a history of VTE that occurred at least 6 months prior. Patients prescribed rivaroxaban or apixaban from December 2, 2021, until June 1, 2022, were included. Pregnant women and patients on apixaban or rivaroxaban for indications other than VTE were excluded. The primary outcome was the proportion of patients on reduced-dose vs full-dose apixaban or rivaroxaban. The secondary outcome was the presence of patient-specific characteristics that were more common in patients on reduced-dose vs full-dose anticoagulant. RESULTS: Of the 287 patients who met the eligibility criteria, 214 (74.6%) were prescribed full-dose apixaban or rivaroxaban and 73 (25.4%) were prescribed reduced-dose apixaban or rivaroxaban. Sickle cell disease was more common in patients prescribed full-dose anticoagulant (14.5% vs 2.7%; P = 0.01), and stage 5 chronic kidney disease was more common in patients prescribed reduced-dose anticoagulant (3.3% vs 11%; P = 0.01). Prescribers specialized in hematology/oncology were more likely to prescribe reduced-dose than full-dose anticoagulant (37.0% vs 22.4% of all prescriptions; P = 0.01). CONCLUSION: The majority of patients were prescribed full-dose rivaroxaban or apixaban for extended-phase anticoagulation, despite guidance suggesting use of a reduced dose. Prescribers may consider patient-specific risks for thrombosis and bleeding when selecting a dose of apixaban or rivaroxaban for VTE prevention.
引用
- Patel M, Mei C, Shapiro NL, et al. Prescribing patterns of apixaban and rivaroxaban for extended-phase anticoagulant therapy. Am J Health Syst Pharm. 2026. PMID: 41635227. doi:10.1093/ajhp/zxag026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。